GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Catheter Precision Inc (AMEX:VTAK) » Definitions » Return-on-Tangible-Asset

Catheter Precision (Catheter Precision) Return-on-Tangible-Asset : -51.16% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Catheter Precision Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Catheter Precision's annualized Net Income for the quarter that ended in Dec. 2023 was $-2.68 Mil. Catheter Precision's average total tangible assets for the quarter that ended in Dec. 2023 was $5.23 Mil. Therefore, Catheter Precision's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -51.16%.

The historical rank and industry rank for Catheter Precision's Return-on-Tangible-Asset or its related term are showing as below:

VTAK' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -728.36   Med: -94.72   Max: -71.93
Current: -728.36

During the past 8 years, Catheter Precision's highest Return-on-Tangible-Asset was -71.93%. The lowest was -728.36%. And the median was -94.72%.

VTAK's Return-on-Tangible-Asset is ranked worse than
99.3% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: -2.43 vs VTAK: -728.36

Catheter Precision Return-on-Tangible-Asset Historical Data

The historical data trend for Catheter Precision's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catheter Precision Return-on-Tangible-Asset Chart

Catheter Precision Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial -96.44 -93.00 -92.03 -141.84 -664.08

Catheter Precision Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -190.26 -1,783.63 -59.62 -108.21 -51.16

Competitive Comparison of Catheter Precision's Return-on-Tangible-Asset

For the Medical Devices subindustry, Catheter Precision's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catheter Precision's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Catheter Precision's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Catheter Precision's Return-on-Tangible-Asset falls into.



Catheter Precision Return-on-Tangible-Asset Calculation

Catheter Precision's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-70.572/( (16.836+4.418)/ 2 )
=-70.572/10.627
=-664.08 %

Catheter Precision's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-2.676/( (6.043+4.418)/ 2 )
=-2.676/5.2305
=-51.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


Catheter Precision  (AMEX:VTAK) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Catheter Precision Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Catheter Precision's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Catheter Precision (Catheter Precision) Business Description

Traded in Other Exchanges
Address
1670 Highway 160 West, Suite 205, Fort Mill, SC, USA, 29708
Catheter Precision Inc Formerly Ra Medical Systems Inc is a commercial-stage medical device company whose business comprises of the design, manufacture and sale of new medical technologies in the field of cardiac electrophysiology, or EP. Its product, View into Ventricular Onset System or VIVO System which is a non invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. . It operates business as one segment which includes all activities related to the marketing, sales and development of medical technologies in the field of cardiac EP.
Executives
David A Jenkins director, officer: Executive Chairman of Board P.O. BOX 682838, PARK CITY UT 84068
Steven K Passey officer: Chief Financial Officer 3216 SOUTH HIGHLAND DRIVE, SUITE 200, SALT LAKE CITY UT 84117
James Joseph Caruso director 28 FIRST AVE, SEASIDE PARK NJ 08752
Brian Conn officer: Chief Financial Officer MICROISLET, INC., 6370 NANCY RIDGE DRIVE, SUITE 112, SAN DIEGO CA 92121
Andrew C. Jackson officer: CFO & Secretary 11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130
Jonathan Will Mcguire director, officer: Chief Executive Officer 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Susanne Meline director P.O. BOX 515381, #86506, LOS ANGELES CA 90051
Martin J Colombatto director
Richard Jr Mejia director 2200 FARADAY AVENUE, SUITE 100, CARLSBAD CA 92008
William R Enquist director 11810 WILLS ROAD, ALPHARETTA GA 30009
Joan Stafslien director CAREFUSION CORPORATION, 3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Daniel Horwood officer: General Counsel C/O RA MEDICAL SYTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD CA 92011
Jeffrey J Kraws officer: Co-President 3985 RESEARCH PARK DRIVE, ANN ARBOR MI 48108
Dean Irwin director, 10 percent owner, officer: See Remarks C/O RA MEDICAL SYSTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD CA 92011
Martin Burstein 10 percent owner C/O RA MEDICAL SYSTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD CA 92011